Stricken language would be deleted from and underlined language would be added to the law as it existed prior to this session of the General Assembly.

1	State of Arkansas As Engrossed: H4/1/05	
2	85th General Assembly A Bill	
3	Regular Session, 2005 HOUSE BILL	2781
4		
5	By: Representative Elliott	
6	By: Senators Steele, Critcher, Whitaker	
7		
8		
9	For An Act To Be Entitled	
10	THE COLORECTAL CANCER ACT OF 2005; AND FOR OTHER	
11	PURPOSES.	
12		
13	Subtitle	
14	THE COLORECTAL CANCER ACT OF 2005.	
15		
16		
17	BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:	
18		
19	SECTION 1. Arkansas Code Title 20, Chapter 15, is amended to add an	a
20	additional subchapter to read as follows:	
21	<u>20-15-1701. Title.</u>	
22	This subchapter shall be known and may be cited as the "Colorectal	
23	Cancer Act of 2005".	
24 25	20-15-1702. Findings and purpose.	
26	(a) The General Assembly finds that:	
20	(1) Colorectal cancer is a significant threat to the health of	of
28	Arkansas residents;	<u> </u>
29	(2) Colorectal cancer is more likely to occur as people get	
30	older. More than ninety percent (90%) of people with this disease are	
31	diagnosed after age fifty (50);	
32	(3) In Arkansas, it is estimated that one thousand six hundre	ed
33	thirty (1,630) new cases of cancer of the colon and rectum will occur in	
34	<u>2005;</u>	
35	(4) Colorectal cancer exacts an enormous economic toll on our	<u>r</u>
36	society in direct medical costs and indirect costs, such as lost work due	to



HB2781

1	illness and shortened lives among experienced workers;
2	(5) Colorectal cancer is largely preventable; and
3	(6) Screening for colorectal cancer can identify the precursors
4	of cancer before the disease begins and the precursors can be removed, thus
5	preventing the emergence of any colorectal cancer.
6	(b) This subchapter is intended to reduce the physical and economic
7	burden of colorectal cancer in Arkansas by supporting research and cancer
8	control activities.
9	20-15-1703. Colorectal Cancer Control and Research Program
10	Demonstration Project.
11	(a) There is established within the Arkansas Cancer Research Center at
12	the University of Arkansas for Medical Sciences in collaboration with the
13	Department of Health a Colorectal Cancer Control and Research Program.
14	(b)(1) The first phase of this program shall be the Colorectal Cancer
15	Control Demonstration Project.
16	(2) The goal of the demonstration project is to:
17	(A) Assess the resources in this state that will enable
18	Arkansas residents to obtain colorectal screening examinations and laboratory
19	tests, to include a fecal occult blood test, double contrast barium enema,
20	flexible sigmoidoscopy, and colonoscopy; and
20 21	<u>flexible sigmoidoscopy, and colonoscopy; and</u> (B) Plan and implement an educational and screening
21	(B) Plan and implement an educational and screening
21 22	(B) Plan and implement an educational and screening intervention program.
21 22 23	<u>(B) Plan and implement an educational and screening</u> <u>intervention program.</u> <u>(c) The demonstration project shall be established at the Arkansas</u>
21 22 23 24	<u>(B) Plan and implement an educational and screening</u> <u>intervention program.</u> <u>(c) The demonstration project shall be established at the Arkansas</u> <u>Cancer Research Center at the University of Arkansas for Medical Sciences and</u>
21 22 23 24 25	<u>(B) Plan and implement an educational and screening</u> <u>intervention program.</u> <u>(c) The demonstration project shall be established at the Arkansas</u> <u>Cancer Research Center at the University of Arkansas for Medical Sciences and</u> <u>shall consist of the following:</u>
21 22 23 24 25 26	(B) Plan and implement an educational and screening intervention program. (c) The demonstration project shall be established at the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences and shall consist of the following: (1) An assessment will be made to:
21 22 23 24 25 26 27	<u>(B) Plan and implement an educational and screening</u> <u>intervention program.</u> <u>(c) The demonstration project shall be established at the Arkansas</u> <u>Cancer Research Center at the University of Arkansas for Medical Sciences and</u> <u>shall consist of the following:</u> <u>(1) An assessment will be made to:</u> <u>(A) Identify the number of facilities in the state that</u>
21 22 23 24 25 26 27 28	(B) Plan and implement an educational and screening intervention program. (c) The demonstration project shall be established at the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences and shall consist of the following: (1) An assessment will be made to: (A) Identify the number of facilities in the state that provide double contrast barium enema, flexible sigmoidoscopy, and
21 22 23 24 25 26 27 28 29	(B) Plan and implement an educational and screening intervention program. (c) The demonstration project shall be established at the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences and shall consist of the following: (1) An assessment will be made to: (A) Identify the number of facilities in the state that provide double contrast barium enema, flexible sigmoidoscopy, and colonoscopy;
21 22 23 24 25 26 27 28 29 30	(B) Plan and implement an educational and screening intervention program. (c) The demonstration project shall be established at the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences and shall consist of the following: (1) An assessment will be made to: (A) Identify the number of facilities in the state that provide double contrast barium enema, flexible sigmoidoscopy, and colonoscopy; (B) Identify physicians, including family practioners,
21 22 23 24 25 26 27 28 29 30 31	(B) Plan and implement an educational and screening intervention program. (c) The demonstration project shall be established at the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences and shall consist of the following: (1) An assessment will be made to: (A) Identify the number of facilities in the state that provide double contrast barium enema, flexible sigmoidoscopy, and colonoscopy; (B) Identify physicians, including family practioners, gastroenterologists, and surgical endoscopists who perform colonoscopy in the
21 22 23 24 25 26 27 28 29 30 31 32	<pre>(B) Plan and implement an educational and screening intervention program. (c) The demonstration project shall be established at the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences and shall consist of the following:</pre>
21 22 23 24 25 26 27 28 29 30 31 32 33	(B) Plan and implement an educational and screening intervention program. (c) The demonstration project shall be established at the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences and shall consist of the following: (1) An assessment will be made to: (A) Identify the number of facilities in the state that provide double contrast barium enema, flexible sigmoidoscopy, and colonoscopy; (B) Identify physicians, including family practioners, gastroenterologists, and surgical endoscopists who perform colonoscopy in the state and the regions of the state in which they practice; (C) Evaluate differences in cost across facilities as

1	(2)(A) Education and screening intervention to demonstrate the
2	effectiveness of providing education and access to screening in order to
3	increase the number of Arkansas residents who obtain screening.
4	(B)(i) The education and screening intervention segment of
5	the demonstration project will enroll Arkansas residents over fifty (50)
6	years of age from multiple sites who are identified as having the highest
7	colorectal cancer incidence and mortality in each of the five (5) regions of
8	the state through the Department of Health's Hometown Health Initiative.
9	(ii) The number of individuals to be enrolled shall
10	be determined by the extent of funding available.
11	(iii) The project segment will study three (3)
12	approaches to education and screening as follows:
13	(a) Provision of an educational intervention
14	designed to teach the individual about the need to seek screening;
15	(b) Provision of access to screening with no
16	educational intervention; and
17	(c) Provision of educational intervention and
18	access together.
19	(iv)(a) Access to screening may include payment
19 20	
	(iv)(a) Access to screening may include payment
20	<u>(iv)(a) Access to screening may include payment</u> vouchers for those patients determined to be underinsured or uninsured.
20 21	<u>(iv)(a) Access to screening may include payment</u> vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by
20 21 22	<u>(iv)(a) Access to screening may include payment</u> <u>vouchers for those patients determined to be underinsured or uninsured.</u> <u>(b) The vouchers shall be redeemable by</u> <u>project participants for screening services obtained through participating</u>
20 21 22 23	<u>(iv)(a) Access to screening may include payment</u> <u>vouchers for those patients determined to be underinsured or uninsured.</u> <u>(b) The vouchers shall be redeemable by</u> <u>project participants for screening services obtained through participating</u> <u>physicians in each of the five (5) regions; and</u>
20 21 22 23 24	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by
20 21 22 23 24 25	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by project leaders to identify the program's effectiveness in increasing the
20 21 22 23 24 25 26	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by project leaders to identify the program's effectiveness in increasing the number of individuals who obtained screening for colorectal cancer.
20 21 22 23 24 25 26 27	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by project leaders to identify the program's effectiveness in increasing the number of individuals who obtained screening for colorectal cancer. (B) The program evaluation information, coupled with the
20 21 22 23 24 25 26 27 28	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by project leaders to identify the program's effectiveness in increasing the number of individuals who obtained screening for colorectal cancer. (B) The program evaluation information, coupled with the results of the assessment of screening resources in this state, will help to
20 21 22 23 24 25 26 27 28 29	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by project leaders to identify the program's effectiveness in increasing the number of individuals who obtained screening for colorectal cancer. (B) The program evaluation information, coupled with the results of the assessment of screening resources in this state, will help to establish strategies for meeting the long-term goal under subsection (d) of
20 21 22 23 24 25 26 27 28 29 30	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by project leaders to identify the program's effectiveness in increasing the number of individuals who obtained screening for colorectal cancer. (B) The program evaluation information, coupled with the results of the assessment of screening resources in this state, will help to establish strategies for meeting the long-term goal under subsection (d) of this section.
20 21 22 23 24 25 26 27 28 29 30 31	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by project leaders to identify the program's effectiveness in increasing the number of individuals who obtained screening for colorectal cancer. (B) The program evaluation information, coupled with the results of the assessment of screening resources in this state, will help to establish strategies for meeting the long-term goal under subsection (d) of this section. (d)(1) The Colorectal Cancer Control and Research Program will build
20 21 22 23 24 25 26 27 28 29 30 31 32	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by project leaders to identify the program's effectiveness in increasing the number of individuals who obtained screening for colorectal cancer. (B) The program evaluation information, coupled with the results of the assessment of screening resources in this state, will help to establish strategies for meeting the long-term goal under subsection (d) of this section.
20 21 22 23 24 25 26 27 28 29 30 31 32 33	(iv)(a) Access to screening may include payment vouchers for those patients determined to be underinsured or uninsured. (b) The vouchers shall be redeemable by project participants for screening services obtained through participating physicians in each of the five (5) regions; and (3)(A) Evaluation at the end of the demonstration period by project leaders to identify the program's effectiveness in increasing the number of individuals who obtained screening for colorectal cancer. (B) The program evaluation information, coupled with the results of the assessment of screening resources in this state, will help to establish strategies for meeting the long-term goal under subsection (d) of this section. (d)(1) The Colorectal Cancer Control and Research Program will build on the results of the demonstration program to meet the long-term goal of the program.

1	(A) Supporting research efforts into the cause, cure,
2	treatment, early detection, and prevention of colorectal cancer and the
3	survivorship of individuals diagnosed with colorectal cancer;
4	(B) Supporting research and educational activities that
5	will inform the public of the value of colorectal cancer screening and will
6	result in improved methods to promote screening and early detection;
7	(C) Supporting policy research to review and analyze long-
8	term successes and future opportunities for reducing the burden of colorectal
9	cancer through legislation;
10	(D) Providing for the full continuum of care, prevention,
11	early detection, diagnosis, treatment, and cure of colorectal cancer; and
12	(E)) Requiring providers to offer a wide range of
13	colorectal cancer screening options.
14	(e)(1) The program shall provide for the full continuum of care,
15	prevention, early detection, diagnosis, treatment, cure of colorectal
16	cancer, and survivorship.
17	(2) The program shall be administered to provide:
18	(A) Colorectal cancer education and awareness to promote
19	prevention and early detection;
20	(B) Colorectal cancer surveillance activities across the
21	state;
22	(C) Screening for colorectal cancer with special focus on
23	persons fifty (50) years of age and older and persons at high risk for
24	colorectal cancer;
25	(D) After-screening, medical referrals, and financial
26	assistance for services necessary to follow up abnormal screening exams;
27	(E) Necessary advocacy and financial assistance to ensure
28	the persons obtain necessary treatment if a positive diagnosis is made; and
29	(F) Obtain information from health care insurers and
30	providers concerning the extent of colorectal cancer screening, treatment,
31	and insurance coverage.
32	
33	SECTION 2. Arkansas Code Title 23, Chapter 79, is amended to add an
34	additional subchapter to read as follows:
35	23-79-1101. Definitions.
36	As used in this subchapter:

HB2781

1	(1) "Covered person" means a person who is and continues to
2	remain eligible for coverage under a health care policy and is covered under
3	a health care policy;
4	(2)(A) "Health care policy" means:
5	(i) An individual or group health insurance policy
6	providing coverage on an expense-incurred basis;
7	(ii) An individual or group service or indemnity type
8	contract issued by a nonprofit corporation;
9	(iii) An individual or group service contract issued by a
10	health maintenance organization;
11	(iv) A group accident and sickness insurance policy issued
12	by a fraternal benefit society, a nonprofit hospital service corporation, a
13	nonprofit medical service corporation, a group health care plan, a health
14	maintenance organization, or any similar entity; and
15	(v) A policy issued by or in connection with:
16	(a) The Arkansas medical assistance program and its
17	contracted insurers, whether providing services on a managed-care or fee-for-
18	service basis;
19	(b) The state employees' and public school teachers'
20	health insurance programs;
21	(c) A self-insured group arrangement to the extent
22	not preempted by federal law; and
23	(d) A managed health care delivery entity of any
24	type or description.
25	(B) "Health care policy" does not include an accident-
26	only, specified disease, hospital indemnity, Medicare supplement, long-term
27	care, disability income, or other limited benefit health insurance policy;
28	and
29	(3) "Persons at high risk for colorectal cancer" means:
30	(A) Individuals over fifty (50) years of age or who face a
31	high risk for colorectal cancer because of:
32	(i) The presence of polyps on a previous
33	colonoscopy, barium enema, or flexible sigmoidoscopy;
34	(ii) Family history of colorectal cancer in close
35	relatives of parents, brothers, sisters, or children;
36	(iii) Genetic alterations of hereditary nonpolyposis

1	<u>colon cancer or familial adenomatous polyposis;</u>
2	(iv) Personal history of colorectal cancer,
3	<u>ulcerative colitis, or Crohn's disease; or</u>
4	(v) The presence of any appropriate recognized gene
5	markers for colorectal cancer or other predisposing factors; and
6	(B) Any additional or expanded definition of "persons at
7	high risk for colorectal cancer" as recognized by medical science and
8	determined by the Director of the Department of Health in consultation with
9	the University of Arkansas for Medical Sciences.
10	
11	23-79-1102. Coverage - Applicability.
12	(a) A health care policy subject to this subchapter executed,
13	delivered, issued for delivery, continued, or renewed in this state on or
14	after August 1, 2005, shall include colorectal cancer examinations and
15	laboratory tests within the policy's coverage.
16	(b) The coverage shall include colorectal cancer examinations and
17	laboratory tests for:
18	(1) Covered persons who are fifty (50) years of age or older;
19	(2) Covered persons who are less than fifty (50) years of age
20	and at high risk for colorectal cancer according to American Cancer Society
21	colorectal cancer screening guidelines as they existed on January 1, 2005;
22	and
23	(3) Covered persons experiencing the following symptoms of
24	colorectal cancer as determined by a physician licensed under the Arkansas
25	Medical Practices Act, §§ 17-95-201 et seq., 17-95-301 et seq., and 17-95-401
26	<u>et seq.:</u>
27	(A) Bleeding from the rectum or blood in the stool; or
28	(B) A change in bowel habits, such as diarrhea,
29	constipation, or narrowing of the stool, that lasts more than five (5) days.
30	(c) After August 1, 2005, each employer that offers a health care
31	policy to employees shall offer all eligible employees at the time of hiring
32	or health care policy renewal a policy that includes colorectal cancer
33	examinations and laboratory tests within the coverage of the employee's
34	health care policy.
35	(d)(1) The colorectal screening shall involve an examination of the
36	entire colon, including:

HB2781

1	(A) The following examinations or laboratory tests, or
2	both:
3	(i) An annual fecal occult blood test utilizing the
4	take-home multiple sample method, or an annual fecal immunochemical test in
5	conjunction with a flexible sigmoidoscopy every five (5) years;
6	(ii) A double-contrast barium enema every five (5)
7	years; or
8	(iii) A colonoscopy every ten (10) years; and
9	(B) Any additional medically recognized screening tests
10	for colorectal cancer required by the Director of the Department of Health,
11	determined in consultation with appropriate health care organizations.
12	(2) The covered person shall determine the choice of screening
13	strategies in consultation with a health care provider.
14	(3) Colorectal screening examinations shall be according to the
15	choices and frequency provided by this subsection (d) for all other covered
16	persons.
17	(e) Screenings shall be limited to the following guidelines for the
18	management or subsequent need for follow-up colonoscopy:
19	(1) If the initial colonoscopy is normal follow-up is
20	recommended in ten (10) years;
21	(2) For individuals with one (1) or more neoplastic polyps,
22	adenomatous polyps, assuming that the initial colonoscopy was complete to the
23	cecum and adequate preparation and removal of all visualized polyps follow-up
24	is recommended in three (3) years;
25	(3) If single tubular adenoma of less than one centimeter (< 1
26	cm) is found follow-up is recommended in five (5) years; and
27	(4) For patients with large sessile adenomas greater than three
28	centimeters (> 3 cm), especially if removed in piecemeal fashion, follow-up
29	is recommended in six (6) months or until complete polyp removal is verified
30	by colonoscopy.
31	
32	23-79-1103. Certain activities not prohibited.
33	(a) This subchapter does not prohibit the issuance of policies that
34	provide benefits greater than those required by § 23-79-1102 or more
35	favorable to the insured than those required by § 23-79-1102.
36	(b) This subchapter does not prohibit the payment of different levels

1	of benefits or from having differences in coinsurance percentages applicable
2	to benefit levels for services provided by preferred and nonpreferred
3	providers as otherwise authorized by law relating to preferred provider
4	arrangements.
5	
6	23-79-1104. Exclusions and reductions Benefits subject to annual
7	deductible and co-insurance.
8	(a) Except as provided in subsection (b) of this section, the coverage
9	offered under § 23-79-1102 may contain any exclusions, reductions, or other
10	limitations approved by the Insurance Commissioner concerning coverages,
11	deductibles, or coinsurance provisions.
12	(b) The benefits provided in this subchapter shall be subject to the
13	same annual deductible or coinsurance established for all other covered
14	benefits within a health care policy.
15	
16	23-79-1105. Coverage by participating providers Selection criteria
17	and utilization protocols Maximum benefits Exclusions.
18	(a)(1) This subchapter does not require and shall not be construed to
19	require the coverage of services by providers who are not designated as
20	covered providers or that are not selected as a participating provider by a
21	group health benefit plan or insurer having a participating network of
22	service providers.
23	(2) This subchapter does not expand the list or designation of
24	participating providers as specified in any health benefit plan.
25	(b) Insurers or other issuers of any health benefit plan covered by
26	this subchapter may continue to establish and apply selection criteria and
27	utilization protocols for health care providers including:
28	(1) The designation of types of providers for which coverage is
29	provided; and
30	(2) Credentialing criteria used in the selection of providers.
31	(c) A health care policy that provides coverage for the services
32	offered under this subchapter may contain provisions for maximum benefits and
33	coinsurance limitations, deductibles, exclusions, and utilization review
34	protocols to the extent that the provisions are not inconsistent with the
35	requirements of this subchapter.
36	

1	23-79-1106. Additional benefit costs.
2	The issuer of a health care policy shall conform its policies,
3	contracts, or certificates issued on or after August 1, 2005, and may adjust
4	its premium cost to reflect the additional benefit cost.
5	
6	<u>23-79-1107. Cost-sharing.</u>
7	(a) To encourage colorectal cancer screenings, patients and health
8	care providers may not be required to meet burdensome criteria or overcome
9	significant obstacles to obtain coverage.
10	(b) An individual shall not be required to pay an additional
11	deductible or coinsurance for testing that is greater than an annual
12	deductible or coinsurance established for similar benefits.
13	(c) If the program or contract does not cover a similar benefit, a
14	deductible or coinsurance may not be set at a level that materially
15	diminishes the value of the colorectal cancer benefit required under this
16	subchapter.
17	(d) Reimbursement to health care providers for colorectal cancer
18	screenings provided under this section shall be equal to or greater than
19	reimbursement to health care providers under Medicare, Title XVII of the
20	Social Security Act, 42 U.S.C. § 1395 et seq., as it existed on January 1,
21	2005.
22	
23	23-79-1108. Referrals to participating providers.
24	A health care policy is not required to provide a referral under this
25	subchapter to a nonparticipating health care provider unless the plan or
26	carrier does not have a participating health care provider that is available
27	and accessible to administer the screening, examination, or treatment of
28	colorectal cancer.
29	
30	23-79-1109. Payment of nonparticipating providers.
31	If a health care policy refers an individual under this subchapter to a
32	nonparticipating health care provider, then services provided under the
33	approved screening exam or resulting treatment, if any, shall be provided at
34	no additional cost to the individual beyond what the individual would
35	otherwise pay to a participating health care provider.
36	

1	SECTION 3. EMERGENCY CLAUSE. It is hereby found and determined that
2	colorectal cancer is a leading cause of death among Arkansas residents; that
3	this number of deaths will increase as our population grows older; that
4	colorectal cancer is a preventable disease; that information barriers result
5	in Arkansas residents being unaware of the risk of colorectal cancer or the
6	value of screening, prevention, and early detection; that financial barriers
7	prevent some Arkansas residents from taking advantage of screening; and that
8	there is a lack of funding to provide for screening, diagnostic, and
9	treatment services for persons at risk of colorectal cancer. Therefore, this
10	act being necessary for the preservation of the public peace, health, and
11	safety shall be in full force and effect from and after August 1, 2005.
12	
13	/s/ Elliott
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	